MedTrace Logo

Capsaicin for Cerebral Perfusion Augmentation

NCT05543837 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-03-14

No results posted yet for this study

Summary

To determine the effect of capsaicin upon serial transcranial Doppler (TCD) markers of cerebral blood flow (CBF). Methods Serial TCD testing in 30 participants with cerebrovascular risk factors. Capsaicin doses .66 and .99 μMol. Outcomes: peak systolic and end-diastolic velocities in the middle cerebral artery (MCA), mean velocity (MV), pulsatility index (PI), CBF index, arterial pressure, and perceived pungency (PP) in five minutes intervals up to 20 minutes.

Conditions

  • Cerebral Circulatory Disorder

Interventions

DRUG

Capsaicin

Patients will receive a fixed dose of capsaicin

Sponsors & Collaborators

  • Centenario Hospital Miguel Hidalgo

    collaborator OTHER

  • Instituto Mexicano del Seguro Social

    lead OTHER_GOV

Principal Investigators

  • Juan M Marquez-Romero, MD, MSc · Unidad de Medicina de Alta Especialidad, Torre Medica CMQ

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-20
Primary Completion
2022-09-30
Completion
2023-02-28

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05543837 on ClinicalTrials.gov